Sartorius Stedim Biotech SA
PAR:DIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Warby Parker Inc
NYSE:WRBY
|
US |
|
3M India Ltd
NSE:3MINDIA
|
IN |
|
N
|
Nakayamafuku Co Ltd
TSE:7442
|
JP |
|
Sleep Country Canada Holdings Inc
TSX:ZZZ
|
CA |
|
Nacity Property Service Group Co Ltd
SSE:603506
|
CN |
|
P
|
PALTAC Corp
TSE:8283
|
JP |
|
Meiko Electronics Co Ltd
TSE:6787
|
JP |
|
Shanghai Lujiazui Finance & Trade Zone Development Co Ltd
SSE:600663
|
CN |
|
AMREP Corp
NYSE:AXR
|
US |
|
K
|
KebNi AB (publ)
STO:KEBNI B
|
SE |
|
A
|
Arena Group Holdings Inc
AMEX:AREN
|
US |
|
P
|
Playmates Holdings Ltd
HKEX:635
|
HK |
|
T
|
Tibet Urban Development and Investment Co Ltd
SSE:600773
|
CN |
Sartorius Stedim Biotech SA
Note Receivable
Sartorius Stedim Biotech SA
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Note Receivable
€240k
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
|
Sartorius Stedim Biotech SA
Glance View
Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.